A phase IIa trial will investigate the efficacy, tolerability and pharmacokinetics of NB 001 (0.025%, 0.05% and 0.10%) when administered to patients with recurrent Herpes labialis.

Trial Profile

A phase IIa trial will investigate the efficacy, tolerability and pharmacokinetics of NB 001 (0.025%, 0.05% and 0.10%) when administered to patients with recurrent Herpes labialis.

Completed
Phase of Trial: Phase II

Latest Information Update: 07 May 2018

At a glance

  • Drugs NB 001 (Primary)
  • Indications Herpes labialis
  • Focus Therapeutic Use
  • Sponsors BlueWillow Biologics; NanoBio Corporation
  • Most Recent Events

    • 07 May 2018 According to a BlueWillow Biologics media release, NanoBio Corporation has changed its name to BlueWillow Biologics.
    • 08 Feb 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top